



E. I. DU PONT DE NEMOURS & COMPANY
INCORPORATED

HASKELL LABORATORY FOR TOXICOLOGY
AND INDUSTRIAL MEDICINE
P.O. BOX 50, ELKTON ROAD
NEWARK, DELAWARE 19714

cc: B. W. Karrh, ERD, N-13510
P. G. Gilby, ERD, B-17249-11
R. C. Graham
A. M. Kaplan
G. L. Kennedy
H. J. Trochimowicz
Central File

CENTRAL RESEARCH AND DEVELOPMENT DEPARTMENT

January 8, 1990

To: K. D. Dastur
C&P Department
B-12308

From: C. F. Reinhardt, M.D. *CFR*
CR&D Department
Haskell Laboratory

R. N. Ligo, M.D. *RVL*
ER Department
N-11400

Lead and Lead Compounds

Ref.: Hazard Determination Letter of 7/10/89
P. G. Gilby's Letter of 10/18/89
K. D. Dastur's Letter of 12/28/89

This letter is being written to complete the follow-up to the hazard determination and development of control programs as prescribed in the EQC Guidelines II C-1, "Control of Carcinogenic, Reproduction and Developmental Risks Posed by Chemicals Made or Used within Du Pont."

Your letter of December 28 and P. G. Gilby's letter of October 18, 1989 indicate that C&P Department (Chambers Works) and all plants worldwide with the potential for occupational exposure to lead are now reviewing their blood-lead data and will begin development of control plans aimed at achieving the new blood-lead goal of less than 15 ug/dl for all females of child bearing capability and of less than 35 ug/dl for all other employees. Additionally, you indicated that the toxicological data for lead have been communicated to all concerned employees.

Based on this information, we believe the communications and control programs for lead are appropriate.

B. W. Karrh, M.D., Vice President of Safety, Health and Environmental Affairs agrees with this assessment.

AMK/eml(2.40)

DWS 1031380

DUP040011171